NANO THERAPIES. MEGA RESULTS.®
Nami Therapeutics Corp (’Nami’) is a startup company based in Storrs, CT and currently participating in the Technology Incubation Program at the University of Connecticut. Nami is developing specifically designed nanoparticles for the targeted delivery of therapeutic agents, including radio-therapeutics, to tumors. Nami is using technologies licensed from the University of Connecticut and the University of North Carolina. The mission of Nami is to provide early, recurrent and late-stage cancer patients another chance for a cancer-free life. The current focus is to treat advanced ovarian cancer using tumor-specific delivery of radioisotope loaded nanoparticles. Nami is translating its nanotechnology-based products to the clinical trial stage by demonstrating their efficacy in preclinical models, and by completing IND enabling activities such as manufacturing process development (CMC) and safety/toxicity assessments.View More
New nanotechnology approaches are needed for delivering chemotherapy drugs and radiotherapeutic agents to tumors in order to improve their efficacy and reduce unwanted side effects.
美国康涅狄格大学终身教授，在纳米技术用于癌症治疗方面有突破性进展
美国药学家协会院士 拥有超过37年的药剂学和影像科学研究经验
拥有超过20年的药企经历：成功促成年销售上几十亿美元产品的国际战略合作
高级科学家，项目负责人和学术带头人，多年的大中小型制药企业和学术界经历
主任医生，哈特福德癌症研究所，哈特福德医院
美国远程医疗业的先驱,领头人,富有远见卓识的商业领袖
Jeff 是 KASTx Ventures 的合伙人，TSP Therapeutics 的联合创始人
